Loading clinical trials...
Loading clinical trials...
Primary Objective: \- To evaluate the efficacy of SAR245409 as determined by the objective response rate (ORR) in patients with 1 of following relapsed or refractory lymphoma or leukemia subtypes: ma...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Sanofi
NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma
NCT04570423 · Solid Tumors, Lymphoma
NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT07545603 · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, and more
Investigational Site Number 840012
Los Angeles, California
Investigational Site Number 840104
Fort Meyers, Florida
Investigational Site Number 840006
Augusta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions